Appendix 4E and FY26 Annual Report
Filed with ASX · · 93 pages · English
Summary by 6ix AI
The report highlights a decrease in operational losses compared to the previous year, attributed to reduced research and development expenditures. The company also reported positive preclinical data and successful regulatory inspections, reinforcing its position in the fight against antimicrobial resistance.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Recce Pharmaceuticals Ltd. on 6ix
In the deck
Earlier from Recce Pharmaceuticals
- Appendix 4G
- HREC Approves Comparator Study for Pivotal Phase 3 DFI
- Change of Director's Interest Notices (x4)
- Cleansing Notice
- Application for quotation of securities - RCE
Later from Recce Pharmaceuticals
- General Meeting Presentation
- Results of General Meeting
- 2026 Annual General Meeting
- Resolutions under section 249N of the Corporations Act
- Notification of cessation of securities - RCE
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals